PART I Overview We are a clinical stage biopharmaceutical company engaged in drug research and development to create new therapies for fibrotic disease, cancer and selected other diseases. Our drug candidates are based on our method of targeting galectin proteins, which are key mediators of biologic and pathologic functions. We use naturally occurring, readily-available plant products as starting material in manufacturing processes to create proprietary, patented complex carbohydrates with speci...
Q2 FY2026 — expected 2026-09-09
| Filed | Period | Accession | Source | Full Text |
|---|---|---|---|---|
| 2026-03-31 | 2025-12-31 | 0001140361-26-012155 | EDGAR | 63K words |
| 2025-03-31 | 2024-12-31 | 0001140361-25-011169 | EDGAR | — |
| 2024-03-29 | 2023-12-31 | 0001140361-24-016452 | EDGAR | — |
| 2023-03-30 | 2022-12-31 | 0001140361-23-014658 | EDGAR | — |
| 2022-03-31 | 2021-12-31 | 0001140361-22-012058 | EDGAR | — |
| 2021-03-31 | 2020-12-31 | 0001193125-21-101402 | EDGAR | — |
| 2020-03-16 | 2019-12-31 | 0001193125-20-073907 | EDGAR | — |
| 2019-03-06 | 2018-12-31 | 0001193125-19-064705 | EDGAR | — |
| 2018-03-29 | 2017-12-31 | 0001193125-18-100592 | EDGAR | — |
| 2017-03-28 | 2016-12-31 | 0001193125-17-098753 | EDGAR | — |
| Filed | Period | Accession | Source | Full Text |
|---|---|---|---|---|
| 2025-11-14 | 2025-09-30 | 0001140361-25-042116 | EDGAR | 24K words |
| 2025-08-14 | 2025-06-30 | 0001140361-25-031039 | EDGAR | — |
| 2025-05-15 | 2025-03-31 | 0001140361-25-019149 | EDGAR | — |
| 2024-11-14 | 2024-09-30 | 0001140361-24-046726 | EDGAR | — |
| 2024-08-13 | 2024-06-30 | 0001140361-24-036937 | EDGAR | — |
| 2024-05-15 | 2024-03-31 | 0001140361-24-026105 | EDGAR | — |
| 2023-11-13 | 2023-09-30 | 0001140361-23-052729 | EDGAR | — |
| 2023-08-14 | 2023-06-30 | 0001140361-23-039411 | EDGAR | — |
| 2023-05-15 | 2023-03-31 | 0001140361-23-024499 | EDGAR | — |
| 2022-11-14 | 2022-09-30 | 0001140361-22-041167 | EDGAR | — |
| 2022-08-15 | 2022-06-30 | 0001140361-22-029555 | EDGAR | — |
| 2022-05-16 | 2022-03-31 | 0001140361-22-019248 | EDGAR | — |
| Filed | Accession | Source | Full Text |
|---|---|---|---|
| 2026-08-04 | 0001140361-26-031058 | EDGAR | — |
| 2026-03-31 | 0001140361-26-012158 | EDGAR | 2K words |
| 2026-03-17 | 0001140361-26-009735 | EDGAR | — |
| 2026-01-21 | 0001140361-26-001866 | EDGAR | — |
| 2026-01-12 | 0001140361-26-000994 | EDGAR | — |
| 2025-12-19 | 0001140361-25-046115 | EDGAR | — |
| 2025-12-08 | 0001140361-25-044711 | EDGAR | — |
| 2025-12-03 | 0001140361-25-044148 | EDGAR | — |
| 2025-11-14 | 0001140361-25-042118 | EDGAR | — |
| 2025-11-10 | 0001140361-25-041275 | EDGAR | — |
342 total filings indexed. 310 additional filings (S-1, DEF 14A, etc.) View all (JSON) · SEC EDGAR
| CIK | 0001133416 |
| Ticker | GALT |
| Exchange | Nasdaq |
| SIC | 2834: Pharmaceutical Preparations |
| Incorporated | NV |
| Website | https://www.galectintherapeutics.com |
| Listed | 2002-09-04 |
This is a static snapshot. For live, structured JSON with cryptographic provenance chain:
MCP (recommended for AI): claude mcp add origin --transport http https://origin.rootz.global/mcp
Try it — paste this into your AI:
Works in ChatGPT, Claude, Gemini, or any AI. Free, structured, cryptographically signed — ~500 tokens vs 130,000 scraping an IR site.
claude mcp add origin --transport http https://origin.rootz.global/mcpGET https://origin.rootz.global/api/company/GALT (~200 tokens, structured JSON with cryptographic provenance)